Search Results - therapeutics+%3e+vaccines

11 Results

Sort By:

Kaposi Sarcoma Associated Herpesvirus Vaccine Development (UCLA Case No. 2023-038)

UCLA researchers in the Department of Molecular and Medical Pharmacology have a novel discovery showing the potential benefit of engaging complement-mediated antibody functions in future KSHV vaccine development. BACKGROUND: Kaposi Sarcoma Associated Herpesvirus (KHSV) is the etiological agent for cancers such as Kaposi Sarcoma (KS) and primary...

Published: 4/16/2024 | Inventor(s): Ting-Ting Wu

Keywords(s): herpes, herpesvirus, kaposi sarcoma, Vaccines

Category(s): Therapeutics > Vaccines

2022-197 Novel Live Multi-Antigenic Recombinant Vaccine Against Tuberculosis

SUMMARY: Researchers at UCLA’s School of Medicine have developed a potent multi-antigen vaccine for protection against tuberculosis. BACKGROUND: Tuberculosis (TB) is an infectious disease that, when active, can affect many organs in the body but can especially cause severe lung disease manifest by chronic cough, fever, and weight loss, and, if...

Published: 2/23/2024 | Inventor(s): Marcus Horwitz

Keywords(s):

Category(s): Therapeutics, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Vaccines

2022-017: Single and Multi-Epitope Peptide and mRNA Vaccines to Generate Tolerogenic Effects for Allergic and Autoimmune Disease by Targeting Liver Sinusoidal Endothelial Cells

SUMMARY: UCLA researchers in the School of Medicine and California NanoSystems Institute have developed a novel treatment method utilizing intravenously-delivered nanoparticles loaded with epitopes that interfere with the anaphylaxis response for sustained tolerance to food allergens. BACKGROUND: The U.S. Food and Drug Administration (FDA) defines...

Published: 9/5/2023 | Inventor(s): Andre Nel

Keywords(s):

Category(s): Therapeutics, Therapeutics > Autoimmune, Therapeutics > Vaccines

2021-174: TCR ALPHA/BETA SEQUENCES REACTIVE WITH HLA-A*02:01 RESTRCITED EPITOPES WITHIN NSP12 PROTEIN OF SARS-COV-2 VIRUS

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have developed a novel way to use the sequencing information from T cell mediated immune responses to profile TCR alpha/beta sequences against SARS-CoV-2 virus. This invention has potential to help develop therapeutics or characterize and produce a long-term...

Published: 11/15/2024 | Inventor(s): Owen Witte, Pavlo Nesterenko, Jami Witte

Keywords(s):

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Vaccines, Therapeutics > Immunology And Immunotherapy

2022-085: MULTI-EPITOPE MRNA SARS-COV-2 VACCINE FOR BOOSTING IMMUNITY THROUGH THE ACTIVATION OF CD4 AND CD8 T CELLS AS WELL AS B LYMPHOCYTES

SUMMARY: UCLA Researchers in the Division of Nanomedicine and Microbiology, Immunology and Molecular Genetics have developed a new SARS-CoV-2 vaccine that provides long lasting and robust immunity. BACKGROUND: An effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major global health priority. While multiple...

Published: 11/15/2024 | Inventor(s): Andre Nel, Tian Xia, Jeffery Miller

Keywords(s):

Category(s): Therapeutics, Therapeutics > Infectious Diseases, Therapeutics > Vaccines, Therapeutics > Infectious Diseases > COVID

2020-871 SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19

UCLA researchers in the Department of Medicine have utilized a highly attenuated replicating bacterial vector platform to develop a vaccine against SARS-CoV-2 in humans and animals to prevent COVID-19. BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), closely related to SARS-CoV, is an enveloped, single-stranded positive RNA...

Published: 2/29/2024 | Inventor(s): Marcus Horwitz

Keywords(s): Infectious Diseases, Therapeutics & Vaccines, Vaccines, Viral Delivery Systems

Category(s): Therapeutics > Vaccines, Therapeutics > Infectious Diseases, Therapeutics > Infectious Diseases > COVID

2019-880 ZIKA VIRUS-BASED ONCOLYTIC THERAPY FOR BRAIN CANCER

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed a novel zika virus-based oncolytic therapy to treat brain cancer.BACKGROUND: Glioma is a type of brain tumor that accounts for 80% of all primary malignant brain tumors. Standard therapy for high-grade glioma requires a combination of surgical resection, radiation...

Published: 9/12/2023 | Inventor(s): Vaithilingaraja Arumugaswami, David Nathanson

Keywords(s): Cns, Drug Delivery, Gene Editing Systems, Gene Therapy, Immunology, Immunotherapy, Oncology, Oncology Immunotherapy, Plasmids / Vectors, Therapeutics & Vaccines, Viral Delivery Systems

Category(s): Diagnostic Markers > Immunology, Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Gene Therapy And Editing, Therapeutics > Oncology > Oncology Immunotherapy

2015-341 COMBINATIONS OF CHECKPOINT INHIBITORS AND DENDRITIC CELL VACCINES TO TREAT BRAIN CANCER

UCLA researchers in the Departments of Neurosurgery and Molecular and Medical Pharmacology have developed an autologous dendritic cell (DC) vaccine in combination with checkpoint inhibitors for the treatment of malignant brain tumors.BACKGROUND: Checkpoint inhibitor therapies, which unblock an existing immune response, or unblock the initiation of an...

Published: 7/19/2023 | Inventor(s): Robert Prins, Linda Liau

Keywords(s): Antibodies, Drug Delivery, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), Oncology Immunotherapy, Therapeutics & Vaccines, Vaccines

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Vaccines, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

2010-657 Novel Live Recombinant Booster Vaccine against Tuberculosis

Summary Researchers at UCLA have developed a novel vaccination strategy against tuberculosis in humans and animals. The invention also details the generation of a vaccine against leprosy and other mycobacterial diseases in humans and animals. Background Tuberculosis (TB) infection remains highly prevalent worldwide. The WHO estimates 1.7 million deaths...

Published: 2/29/2024 | Inventor(s):

Keywords(s):

Category(s): Therapeutics > Vaccines

2010-653 Preparation and Activity of Novel Photosensitizer Acting as a Broad Spectrum Antiviral Agent Against Enveloped Viruses

Summary Professor Michael Jung's group at UCLA has developed a novel class of compounds with broad spectrum antiviral activity toward enveloped viruses. Background Advances in antiviral treatments have allowed clinicians to control and manage many life-threatening viral infections. Most notably, these therapies have focused on the treatment of HIV,...

Published: 7/19/2023 | Inventor(s):

Keywords(s):

Category(s): Therapeutics > Vaccines

1 2